Ahead of its acquisition by cancer imaging company Kuva Labs, Lisata Therapeutics has regained the Chinese rights to its lead ...

Cancer imaging company Kuva Labs is expanding its scope via the acquisition of solid tumor biotech Lisata Therapeutics.

Bristol-Myers Squibb Company (NYSE:BMY) is included among the Best Low Risk Stocks for a Retirement Stock Portfolio. Janux ...

Today some of the most aggressive solid tumor cancers remain stubbornly resistant to treatment. There are many reasons why these cancers are difficult to treat, including mutations they may express or ...

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

Exelixis may only have one drug on the market right now, but with phase 3 results for a potential new blockbuster on the horizon and a growing pipeline, the Cabometyx maker is aiming big. | Exelixis ...

Systematic review of 2L+ ADC strategies in triple-negative breast cancer (TNBC). First in human PK analysis of antibody conjugated liposome encapsulating doxorubicin (HF-K1) in advanced cancer ...

Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...

Children with Down syndrome have a significantly increased risk of leukemia, while adults have a lower risk of several common ...

GT Biopharma submitted an IND application for GTB-5550 TriKE for solid tumors. Phase 1 trial planned for 2026.

In the summer of 2025, the University of Louisville Brown Cancer Center became one of the first in the US to offer FDA ...

Scientists at Mount Sinai have unveiled a bold new way to fight metastatic cancer by turning the tumor’s own defenses against ...